-
05 Robert LaCaze-拜耳全球肿瘤研发及业务新方向
Robert LaCaze 总裁拜耳全球肿瘤事业部总裁Robert LaCaze is a senior bio-pharmaceutical executive with more than 28 years of experience in the industry. Throughout his career he has served in multiple operational and strategic roles involving the US, EU, China and Japan.Mr. LaCaze joined Bayer Pharmaceuticals in October 2015 and currently serves as the Executive Vice President and Head of the Oncology Strategic Business Unit (SBU). The Oncology SBU is responsible for all strategy in Bayer’s Oncology Business and consists of: Clinical Development, Regulatory Affairs, Strategic Medical Affairs, Strategic Marketing and Commercialization, Oncology Market Access and Clinical Operations. He is also a member of Bayer’s Pharmaceutical Executive Committee.Prior to joining Bayer, Mr. LaCaze spent over 25 years with Bristol Myers Squibb serving in multiple roles including his two most recent roles of Senior Vice President and Head of Product and Portfolio Strategy for Worldwide Commercialization and Senior Vice President, Global Oncology Commercialization in which he was responsible, with his R&D counterpart, for setting the vision and strategy for the Immuno-Oncology (I-O) franchise. He oversaw the early strategy for Nivolumab and lead the Global Launch of Ipilimumab BMS’s first I-O drug and the Global launch of BMS’s first target therapy, Dasatinib. Both of which have achieved more than $1B in annual sales.Mr LaCaze is a member of AACR and also serves as a member of the College of Business Advisory Board for Louisiana Tech University, his alma mater. He, his wife, and two sons reside in Robbinsville NJ.
2018-04-05 40199 看过 免费 -
03 韩国宏-介入新思路：建立 TACE 技术与靶向药物治疗最佳联合
韩国宏 教授空军军医大学（第四军医大学）西京医院消化介入科主任主任医师、教授、博导亚太原发性肝癌理事会理事（APPLE Council Member）中华医学会放射学分会介入学组副主任委员中国研究型医院学会介入专委会副主任委员中华医学会消化学分会介入协作组副组长卫计委原发性肝癌诊疗规范专家委员会委员（2011 版和 2017 版）2017 年以第一完成人获军队科技进步一等奖2016 年作为主要成员获国家科学进步奖创新团队奖2012 年至 2016 年连续五年荣登中国名医百强榜（介入放射治疗科）2010 年以来作为第一或通讯作者在 Gut、Nat Rev Gastro & Hepatol 、 Hepatology 、 J Hepatol 、 Ann Oncol 、 Clin Cancer Res 、 Radiology、 Thromb & Haemost 等权威杂志发表 SCI 同行评议论文 129 篇
2018-04-05 75574 看过 免费
热门资讯
- 鼓楼医院：全球首个脐带间充质干细胞滴眼液治疗难治性干眼症的临床报告
- 第二届中国老龄健康促进工程卒中救治同质化发展创新大会召开
- COVID-19遇上鲍曼不动杆菌感染：临床不可忽视的双重威胁
- EULAR全球风向标 | URAT1抑制剂鲁兹诺雷钠治疗原发性痛风伴高尿酸血症的三期临床试验取得突破性进展
- 会议预告 | 医防融合，共促发展：聚焦专科医院建设，推进银屑病诊疗规范化！
- 舒巴坦/度洛巴坦治疗严重AB感染（VAP）的单中心病例回顾性研究
- 闫卫红教授访谈：破局戈谢病诊疗困境，推动罕见病MDT诊疗模式快速发展
- 病例解读：舒巴坦-度洛巴坦为全耐药鲍曼不动杆菌感染患者带来治疗新选择
- SIFIC热点速递丨大感控·新防线：后疫情时代三大耐药危机的破局之战
- 牛丰南教授访谈：多学科协作模式开启戈谢病诊疗保障新篇章
